Novellia, Inc.

About Novellia, Inc.

Novellia, Inc. is a biotechnology company developing gene-editing therapeutics for rare inherited retinal diseases. Leveraging proprietary CRISPR-based platforms, the company targets mutations causing vision loss in patients with limited treatment options. Its lead programs focus on Leber congenital amaurosis and retinitis pigmentosa, aiming to restore functional vision through precise in-vivo genome correction. Founded by scientists from UC Berkeley and UCSF, Novellia operates from headquarters in South San Francisco and maintains partnerships with academic medical centers to advance preclinical studies toward human trials.